FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022761070> ?p ?o ?g. }

• W3022761070 abstract "Cystic fibrosis is an inherited condition causing disease most noticeably in the lungs, digestive tract and pancreas. People with cystic fibrosis often have malnutrition and growth delay. Adequate nutritional supplementation does not improve growth optimally and hence an anabolic agent, recombinant growth hormone, has been proposed as a potential intervention.To evaluate the effectiveness and safety of recombinant human growth hormone therapy in improving lung function, quality of life and clinical status of children and young adults with cystic fibrosis.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date of latest search: 11 February 2015.We conducted a search of relevant endocrine journals and proceedings of the Endocrinology Society meetings using Scopus and Proceedings First. Date of latest search: 04 March 2015.Randomised and quasi-randomised controlled trials of all preparations of recombinant growth hormone compared to either no treatment, or placebo, or each other at any dose (high-dose and low-dose) or route and for any duration, in children or young adults aged up to 25 years diagnosed with cystic fibrosis (by sweat test or genetic testing).Two authors independently screened papers, extracted trial details and assessed their risk of bias.Four controlled trials were included in this review (with 161 participants in total), each with an unclear risk of bias. Analysis of data obtained from these trials shows improvement in height for all comparisons, but improvements in weight and lean tissue mass were only reported in the comparison of standard dose recombinant growth hormone versus no treatment. One study showed moderate improvement at one time point in one parameter of pulmonary function tests, forced vital capacity (per cent predicted) when comparing standard dose recombinant growth hormone and no treatment, but there was no consistent benefit in lung function across all studies. Little evidence was found for improvement in quality of life. An improvement in fasting blood glucose levels was reported when comparing rhGH to placebo only. Exercise capacity improved in participants receiving standard dose recombinant growth hormone versus no treatment, but not for any other comparison. There is insufficient evidence to conclude any changes in hospitalisations, antibiotic use or significant adverse effects.Recombinant growth hormone therapy is effective in improving the intermediate outcomes in height, weight and lean tissue mass when compared with no treatment. One measure of pulmonary function test showed moderate improvement at a single time point, but no consistent benefit was seen across all studies. No significant changes in quality of life, clinical status or side-effects were observed in this review. Long-term, well-designed randomised controlled trials of recombinant growth hormone therapy in people with cystic fibrosis are required prior to evaluation of human growth hormone treatment for routine use." @default.
• W3022761070 created "2020-05-13" @default.
• W3022761070 creator A5024121612 @default.
• W3022761070 creator A5032041753 @default.
• W3022761070 creator A5045912789 @default.
• W3022761070 creator A5046465972 @default.
• W3022761070 creator A5059761331 @default.
• W3022761070 date "2015-05-20" @default.
• W3022761070 modified "2023-10-16" @default.
• W3022761070 title "Recombinant growth hormone therapy for cystic fibrosis in children and young adults" @default.
• W3022761070 cites W149298252 @default.
• W3022761070 cites W1875804792 @default.
• W3022761070 cites W1963610361 @default.
• W3022761070 cites W1969302053 @default.
• W3022761070 cites W1970077677 @default.
• W3022761070 cites W1972763246 @default.
• W3022761070 cites W1974930838 @default.
• W3022761070 cites W1983928112 @default.
• W3022761070 cites W1985809072 @default.
• W3022761070 cites W1990862668 @default.
• W3022761070 cites W1998433057 @default.
• W3022761070 cites W2019801728 @default.
• W3022761070 cites W2024862309 @default.
• W3022761070 cites W2025454438 @default.
• W3022761070 cites W2028479357 @default.
• W3022761070 cites W2030338159 @default.
• W3022761070 cites W2035570146 @default.
• W3022761070 cites W2049236612 @default.
• W3022761070 cites W2049308343 @default.
• W3022761070 cites W2050639486 @default.
• W3022761070 cites W2054908401 @default.
• W3022761070 cites W2054931681 @default.
• W3022761070 cites W2056123923 @default.
• W3022761070 cites W2067585296 @default.
• W3022761070 cites W2072738630 @default.
• W3022761070 cites W2088077244 @default.
• W3022761070 cites W2092048896 @default.
• W3022761070 cites W2092763247 @default.
• W3022761070 cites W2094312349 @default.
• W3022761070 cites W2094639448 @default.
• W3022761070 cites W2097338332 @default.
• W3022761070 cites W2101927611 @default.
• W3022761070 cites W2105190712 @default.
• W3022761070 cites W2118829700 @default.
• W3022761070 cites W2119785686 @default.
• W3022761070 cites W2123616746 @default.
• W3022761070 cites W2126809978 @default.
• W3022761070 cites W2129881059 @default.
• W3022761070 cites W2138255371 @default.
• W3022761070 cites W2138317884 @default.
• W3022761070 cites W2139847089 @default.
• W3022761070 cites W2141084299 @default.
• W3022761070 cites W2142930532 @default.
• W3022761070 cites W2146131278 @default.
• W3022761070 cites W2151174404 @default.
• W3022761070 cites W2154192143 @default.
• W3022761070 cites W2163954745 @default.
• W3022761070 cites W2169941450 @default.
• W3022761070 cites W2170363361 @default.
• W3022761070 cites W2170451465 @default.
• W3022761070 cites W2289601957 @default.
• W3022761070 cites W2318605176 @default.
• W3022761070 cites W2319825310 @default.
• W3022761070 cites W2323532050 @default.
• W3022761070 cites W2416454333 @default.
• W3022761070 cites W4211074500 @default.
• W3022761070 cites W4242454765 @default.
• W3022761070 cites W4246904083 @default.
• W3022761070 cites W4251496094 @default.
• W3022761070 doi "https://doi.org/10.1002/14651858.cd008901.pub3" @default.
• W3022761070 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8407505" @default.
• W3022761070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34424546" @default.
• W3022761070 hasPublicationYear "2015" @default.
• W3022761070 type Work @default.
• W3022761070 sameAs 3022761070 @default.
• W3022761070 citedByCount "19" @default.
• W3022761070 countsByYear W30227610702014 @default.
• W3022761070 countsByYear W30227610702015 @default.
• W3022761070 countsByYear W30227610702016 @default.
• W3022761070 countsByYear W30227610702017 @default.
• W3022761070 countsByYear W30227610702018 @default.
• W3022761070 countsByYear W30227610702019 @default.
• W3022761070 countsByYear W30227610702020 @default.
• W3022761070 countsByYear W30227610702021 @default.
• W3022761070 countsByYear W30227610702022 @default.
• W3022761070 crossrefType "journal-article" @default.
• W3022761070 hasAuthorship W3022761070A5024121612 @default.
• W3022761070 hasAuthorship W3022761070A5032041753 @default.
• W3022761070 hasAuthorship W3022761070A5045912789 @default.
• W3022761070 hasAuthorship W3022761070A5046465972 @default.
• W3022761070 hasAuthorship W3022761070A5059761331 @default.
• W3022761070 hasConcept C126322002 @default.
• W3022761070 hasConcept C142724271 @default.
• W3022761070 hasConcept C168563851 @default.
• W3022761070 hasConcept C187212893 @default.
• W3022761070 hasConcept C204787440 @default.
• W3022761070 hasConcept C27081682 @default.
• W3022761070 hasConcept C2776938444 @default.
• W3022761070 hasConcept C535046627 @default.
• W3022761070 hasConcept C71924100 @default.

• next